Abstract
Hyperpolarized 1-13C-2-oxoglutarate as contrast agent in13C Magnetic Resonance diagnostic technique (13C-MRI) for use in the diagnosis of cancer. In particular, upon administration of said 1-13C-2-oxoglutarate, signals of 1-13C-glutamate are detected. More in particular, different MR signals from13C nuclei are detected and compared, said comparison being useful to determine a difference between tumor and non-tumor tissues, to determine the aggressiveness of a tumor or the efficacy of an anti-tumor therapy
Original language | English |
---|---|
IPC | A61K 49/ 10 A I |
Patent number | EP2911704 |
Filing date | 02/09/2015 |
Country | International Bureau of the World Intellectual Property Organization (WIPO) |
Priority date | 24/10/2013 |
Priority number | WO2013EP72269 |
Publication status | Published - 2 Sep 2015 |